Figure 1.
Adjusted percentages of patients with advanced prostate cancer with a filled prescription of abiraterone or enzalutamide were compared between practice types by year by using the least squares means procedure. All statistical tests were 2-sided. In 2015, 2016, and 2017, higher percentages of patients managed by eventually dispensing single-specialty urology practices had a filled prescription of abiraterone or enzalutamide compared with patients managed by nondispensing single-specialty urology practices. The error bars present the 95% confidence intervals.
